We continue to embrace opportunities that may enable the delivery of potentially transformational medicines.

  • GSK

    Our collaboration with GSK aims to advance transformative oligonucleotide therapeutics, including WVE-006 for alpha-1 antitrypsin deficiency (AATD). The collaboration combines GSK’s unique insights from human genetics, as well as its global development and commercial capabilities, with Wave’s PRISMTM platform and oligonucleotide expertise. It has three components:

    • A discovery collaboration which enables Wave to advance up to three programs leveraging targets informed by GSK’s novel insights;
    • A discovery collaboration which enables GSK to advance up to eight programs leveraging Wave’s discovery capabilities and PRISM, including Wave’s three RNA-targeting modalities (editing, splicing, and silencing);
    • An exclusive global license for GSK to WVE-006, Wave’s program for AATD that uses proprietary “AIMer” technology (A-to-I(G) RNA base editing). WVE-006 is a first-in-class RNA editing therapeutic that is designed to address both liver and lung manifestations of the disease. Wave will maintain development responsibilities for WVE-006 through completion of the first clinical study, at which point development and commercial responsibilities will transition to GSK.

    Read the collaboration summary

  • Takeda
    Our collaboration with Takeda Pharmaceuticals aims to accelerate the development of innovative, first-in-class therapies that address central nervous system (CNS) disorders. As part of this strategic partnership, Takeda has an option to a global 50:50 co-development and co-commercialization profit share for select CNS targets, including huntingtin (WVE-003 for Huntington’s disease) and C9orf72 (WVE-004 for amyotrophic lateral sclerosis and frontotemporal dementia).